Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Guido Giordano"'
Autor:
Andrea Palicelli, Martina Bonacini, Stefania Croci, Cristina Magi-Galluzzi, Sofia Cañete-Portillo, Alcides Chaux, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Moira Ragazzi, Maria Paola Bonasoni, Alessandra Soriano, Stefano Ascani, Maurizio Zizzo, Carolina Castro Ruiz, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Daniel M. Berney, Daniel Athanazio, Jatin Gandhi, Alberto Cavazza, Giacomo Santandrea, Alessandro Tafuni, Magda Zanelli
Publikováno v:
Cells, Vol 10, Iss 11, p 3166 (2021)
Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We pe
Externí odkaz:
https://doaj.org/article/bb8e29accbd74f43b44ae3429430e2c6
Autor:
Andrea Palicelli, Martina Bonacini, Stefania Croci, Cristina Magi-Galluzzi, Sofia Cañete-Portillo, Alcides Chaux, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Magda Zanelli, Maria Paola Bonasoni, Loredana De Marco, Alessandra Soriano, Stefano Ascani, Maurizio Zizzo, Carolina Castro Ruiz, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Daniel M. Berney, Jatin Gandhi, Giacomo Santandrea, Maria Carolina Gelli, Alessandro Tafuni, Moira Ragazzi
Publikováno v:
Cells, Vol 10, Iss 11, p 3165 (2021)
Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry,
Externí odkaz:
https://doaj.org/article/49bdba14c7fc4b88b941d1f188ef305f
Autor:
Alessandra Soriano, Moira Ragazzi, Maria Paola Bonasoni, Francesca Sanguedolce, Alessandra Bisagni, Alessandro Tafuni, Matteo Landriscina, Beatrice Melli, Giacomo Santandrea, Giuseppe Carrieri, Alberto Cavazza, Guido Giordano, Sofia Canete-Portillo, Luigi Cormio, Dario de Biase, Antonio De Leo, Stefania Croci, Daniel Abensur Athanazio, Eleonora Zanetti, Alcides Chaux, Cristina Magi-Galluzzi, Andrea Palicelli, Magda Zanelli, Carolina Castro Ruiz, Martina Bonacini, Daniel M. Berney, Jatin Gandhi, Stefano Ascani, Maurizio Zizzo
Publikováno v:
Cells
Cells, Vol 10, Iss 3166, p 3166 (2021)
Cells, Vol 10, Iss 3166, p 3166 (2021)
Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We pe